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In patients with HIV and hepatitis B or C co-infection
initiation of early HAART therapy is clearly recommended
by the international guidelines reflecting the overall survi-
val benefit with regard not only to HIV but also clinical
endpoints of liver disease in the co-infected patient popu-
lation. In patients with hepatitis C co-infection administra-
tion of successful HAART is associated with less
inflammation in liver biopsies and hence, over time less
fibrosis generation. Obviously, drugs which are dually
active against HIV and HBV do not only prevent HIV dis-
ease progression, but also decrease the progression of
chronic hepatitis B related liver disease. Nevertheless,
recent reports on the emergence of non cirrhotic portal
hypertension as a rare cause of upper gastrointestinal
bleeding in HIV patients most likely following prolonged
didanosin exposure have raised questions with regard to
potential drug toxicity as sequelae of HAART causing pos-
sible damage to the liver and the portal vascular system.
Under consideration of metabolic changes including disli-
pidemia and insulin resistance caused by various compo-
nents of different drug classes the question also remains in
how far risk for fatty liver disease may rise after decades of
HAART administration. Therefore, close surveillance pro-
grams and monitoring are required to answer the long
term safety questions around HAART administration and
liver safety. Nevertheless, the clear demonstration of over-
all increased survival under HAART in patients with con-
comitant hepatitis and HIV clearly underlines that the
benefits of HAART outweighs potential toxicity risks. Also
with the knowledge obtained around mitochondrial toxi-
city observed under D-nucleoside therapy treatment algo-
rithms for co-infected patients now specifically refrain
from using these drugs in particular. With the advent of
new drug classes with low hepatotoxicity profiles new
combinations arise which potentially improved liver safety
profile over time. But again, long term data will be needed
to eventually decide what are the best HIV treatment
options in patients with concomitant liver disease.
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